Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Is resistance futile?

Victoria D Kutilek1, Dennis A Sheeter, John H Elder

  • 1Department of Molecular and Experimental Medicine (L55), 10550 North Torrey Pines Rd, The Scripps Research Institute, La Jolla, CA 92037, USA.

Current Drug Targets. Infectious Disorders
|February 3, 2004
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Glycolysis and glycolytic enzymes in acute myeloid leukemia: Warburg and beyond.

Frontiers in pharmacology·2026
Same author

Oncogenic DMTF1β promotes cancer cell motility by regulating autophagy through ULK1 stabilization.

Molecular oncology·2026
Same author

Lenacapavir prevents production of infectious HIV-1 by abrogating immature virus assembly.

bioRxiv : the preprint server for biology·2026
Same author

Identification of DMP1 as Novel p53 Repressed Transcriptional Target.

International journal of molecular sciences·2026
Same author

Targeted recruitment of USP15 enhances CTLA4 surface levels and restricts its degradation.

Life science alliance·2026
Same author

MrHAMER2: high-accuracy long-read RNA sequencing to decode isoform-specific variation in viral transcripts during latency.

bioRxiv : the preprint server for biology·2025

New strategies are needed to design broad-based human immunodeficiency virus (HIV) protease inhibitors to combat multi-drug resistance. Targeting novel protease sites can reduce cross-resistance risks and improve HIV treatment outcomes.

Area of Science:

  • Virology
  • Drug Discovery
  • Molecular Biology

Background:

  • Current human immunodeficiency virus (HIV) treatments target reverse transcriptase (RT) and protease (Pr).
  • Combination therapies have reduced AIDS morbidity and mortality, but drug resistance is a growing concern.
  • Existing protease inhibitors (PIs) target the active site, leading to cross-resistance.

Purpose of the Study:

  • To review HIV protease inhibitor resistance.
  • To discuss new drug design strategies for suppressing protease activity.
  • To explore targeting novel protease sites to overcome multi-drug resistance.

Main Methods:

  • Review of current literature on HIV protease inhibitor resistance.
  • Analysis of structure-function relationships in HIV protease.

Related Experiment Videos

  • Examination of the impact of drug-resistant mutants on HIV-1 protease evolution.

    • Main Results:

    • Treatment failures occur due to non-compliance, toxicity, and emerging drug-resistant mutations.
    • Incomplete viral suppression can lead to HIV-1 escape mutants resistant to all available PIs.
    • Cross-resistance to existing PIs is a significant challenge in HIV treatment.

    Conclusions:

    • New, broad-based protease inhibitors are essential to control multi-drug and cross-resistant HIV-1.
    • Targeting novel structural sites of HIV protease is a promising strategy to reduce drug resistance.
    • Understanding resistance mechanisms is crucial for developing next-generation HIV therapies.